news
Novo Nordisk set to acquire Emisphere for $1.8 billion
Following approval by Emisphere shareholders, Novo Nordisk will acquire the company for a total of $1.8 billion.
List view / Grid view
Novo Nordisk
Filter the results
news
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
article
Has COVID-19 changed public perception of pharmaceutical companies?
EPR’s Hannah Balfour explores pharma’s reputation prior to the pandemic and the impact of COVID-19, highlighting areas which pharma could focus on to improve consumer relations and drive public engagement and trust.
article
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
article
Why product information management is key to success in a changing pharma market
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
news
Novo Nordisk offers free 90-day insulin supply to patients due to COVID-19
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
news
Concizumab haemophilia trials paused over safety concerns
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
news
First oral GLP-1 treatment for type 2 diabetes approved
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
news
Novo Nordisk files lawsuit against Mylan for generic application
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
news
AstraZeneca and Novartis set to lose out from US drug prices reforms
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
news
Global diabetes drug market expected to rise 3.6 percent
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
news
Type 2 diabetes treatment approved for children and adolescents
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
news
Application to EMA filed for the approval of oral semaglutide
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
news
Committee demands answers on rising cost of insulin in the US
Letters have been sent to Eli Lilly, Novo Nordisk and Sanofi asking them to explain the rapidly increasing cost of insulin...
news
Pausing evolution makes bioproduction of chemicals affordable and efficient
Circumventing evolution in cell factories can pave the way for commercialising new biobased chemicals to large-scale.